Indivior PLC Ordinary Shares (INDV) - Total Liabilities

Latest as of September 2025: $1.62 Billion USD

Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) has total liabilities worth $1.62 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Indivior PLC Ordinary Shares (INDV) cash conversion ratio to assess how effectively this company generates cash.

Indivior PLC Ordinary Shares - Total Liabilities Trend (2016–2024)

This chart illustrates how Indivior PLC Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Check INDV asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Indivior PLC Ordinary Shares Competitors by Total Liabilities

The table below lists competitors of Indivior PLC Ordinary Shares ranked by their total liabilities.

Company Country Total Liabilities
Titan Cement International SA
BR:TITC
Belgium €1.37 Billion
Asia Cement Corp
TW:1102
Taiwan NT$121.05 Billion
Cosan S.A
SA:CSAN3
Brazil R$93.68 Billion
Shandong Shida Shenghua Chem
SHG:603026
China CN¥5.31 Billion
Tsinghuatongfang Co Ltd
SHG:600100
China CN¥29.31 Billion
AUMOVIO N
XETRA:AMV0
Germany €9.56 Billion
EO Technics Co. Ltd
KQ:039030
Korea ₩82.71 Billion
BrightGene Bio Medical Technology C
SHG:688166
China CN¥2.80 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Indivior PLC Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see INDV market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.96 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -7.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Indivior PLC Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Indivior PLC Ordinary Shares (2016–2024)

The table below shows the annual total liabilities of Indivior PLC Ordinary Shares from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 $1.67 Billion -14.52%
2023-12-31 $1.95 Billion +12.97%
2022-12-31 $1.73 Billion +6.24%
2021-12-31 $1.63 Billion +12.20%
2020-12-31 $1.45 Billion +0.42%
2019-12-31 $1.44 Billion -2.57%
2018-12-31 $1.48 Billion -10.08%
2017-12-31 $1.65 Billion +9.51%
2016-12-31 $1.50 Billion --

About Indivior PLC Ordinary Shares

NASDAQ:INDV USA Drug Manufacturers - Specialty & Generic
Market Cap
$4.70 Billion
Market Cap Rank
#4208 Global
#1388 in USA
Share Price
$37.66
Change (1 day)
+2.39%
52-Week Range
$10.98 - $37.66
All Time High
$37.66
About

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more